Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study

Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study

Abstract In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has de...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, Wei Li, Lijian Zhang, Bingliang Jiang, Bin Chen, Jinchun Xing, Xuegang Wang
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Tislelizumab
Axitinib
Renal cell carcinoma (RCC)
Inferior vena cava (IVC) tumor thrombus
Neoadjuvant therapy
Online Access:https://doi.org/10.1038/s41598-025-86712-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-86712-6

Similar Items